Cargando…

Pre-existing Immunocompromised Status as a Preventer of Mortality in COVID-19 Patients: Friend or Foe?

Objective COVID-19 has been negatively impacted by a number of comorbidities. Aside from that, some conditions or treatments that cause immunosuppression can alter the course of the disease, leading to worse outcomes. The primary goal of this study is to compare the clinical presentation, laboratory...

Descripción completa

Detalles Bibliográficos
Autores principales: Olgun Yıldızeli, Sehnaz, Vezir, Duygu, Cimsit, Canan, Kocakaya, Derya, Mercanci, Zeynep, Balcan, Baran, Ermerak, Onur, Ilgin, Can, Eryuksel, Emel, Karakurt, Sait
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10186853/
https://www.ncbi.nlm.nih.gov/pubmed/37200662
http://dx.doi.org/10.7759/cureus.37633
_version_ 1785042636077268992
author Olgun Yıldızeli, Sehnaz
Vezir, Duygu
Cimsit, Canan
Kocakaya, Derya
Mercanci, Zeynep
Balcan, Baran
Ermerak, Onur
Ilgin, Can
Eryuksel, Emel
Karakurt, Sait
author_facet Olgun Yıldızeli, Sehnaz
Vezir, Duygu
Cimsit, Canan
Kocakaya, Derya
Mercanci, Zeynep
Balcan, Baran
Ermerak, Onur
Ilgin, Can
Eryuksel, Emel
Karakurt, Sait
author_sort Olgun Yıldızeli, Sehnaz
collection PubMed
description Objective COVID-19 has been negatively impacted by a number of comorbidities. Aside from that, some conditions or treatments that cause immunosuppression can alter the course of the disease, leading to worse outcomes. The primary goal of this study is to compare the clinical presentation, laboratory analysis, radiological findings, and outcomes of patients with COVID-19 with and without immunosuppression. Materials and methods The study includes patients with pre-existing immunosuppression and COVID-19 infection who were admitted and received inpatient treatment at Marmara University Hospital, Istanbul, Pulmonary Medicine ward between April 2020 and June 2020. Data on demographics, epidemiology, clinical course, laboratory analysis, radiological findings, length of hospital stay, morbidity, and mortality were collected from all patients. Results The study group consisted of 23 patients who had pre-existing immunosuppression, and the control group consisted of 207 immunocompetent patients, making a total of 230 patients. Significant differences in lymphocyte count, ROX (respiratory-rate oxygenation) index on Day 0, and fibrinogen levels were discovered between the two groups. SARI (severe acute respiratory infection) was more common in the control group than in the study group (p<0.022), but there was no difference in mortality. Conclusion The mean number and percentage of lymphocytes were lower in immunocompromised COVID-19 patients at the time of diagnosis. Higher ROX index values and a lower risk of developing SARI could explain the hypothesis that these patients may be benefiting from a pre-existing corticosteroid regimen. Additional research with larger numbers of patients may be beneficial in drawing a more definitive conclusion.
format Online
Article
Text
id pubmed-10186853
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-101868532023-05-17 Pre-existing Immunocompromised Status as a Preventer of Mortality in COVID-19 Patients: Friend or Foe? Olgun Yıldızeli, Sehnaz Vezir, Duygu Cimsit, Canan Kocakaya, Derya Mercanci, Zeynep Balcan, Baran Ermerak, Onur Ilgin, Can Eryuksel, Emel Karakurt, Sait Cureus Infectious Disease Objective COVID-19 has been negatively impacted by a number of comorbidities. Aside from that, some conditions or treatments that cause immunosuppression can alter the course of the disease, leading to worse outcomes. The primary goal of this study is to compare the clinical presentation, laboratory analysis, radiological findings, and outcomes of patients with COVID-19 with and without immunosuppression. Materials and methods The study includes patients with pre-existing immunosuppression and COVID-19 infection who were admitted and received inpatient treatment at Marmara University Hospital, Istanbul, Pulmonary Medicine ward between April 2020 and June 2020. Data on demographics, epidemiology, clinical course, laboratory analysis, radiological findings, length of hospital stay, morbidity, and mortality were collected from all patients. Results The study group consisted of 23 patients who had pre-existing immunosuppression, and the control group consisted of 207 immunocompetent patients, making a total of 230 patients. Significant differences in lymphocyte count, ROX (respiratory-rate oxygenation) index on Day 0, and fibrinogen levels were discovered between the two groups. SARI (severe acute respiratory infection) was more common in the control group than in the study group (p<0.022), but there was no difference in mortality. Conclusion The mean number and percentage of lymphocytes were lower in immunocompromised COVID-19 patients at the time of diagnosis. Higher ROX index values and a lower risk of developing SARI could explain the hypothesis that these patients may be benefiting from a pre-existing corticosteroid regimen. Additional research with larger numbers of patients may be beneficial in drawing a more definitive conclusion. Cureus 2023-04-16 /pmc/articles/PMC10186853/ /pubmed/37200662 http://dx.doi.org/10.7759/cureus.37633 Text en Copyright © 2023, Olgun Yıldızeli et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Infectious Disease
Olgun Yıldızeli, Sehnaz
Vezir, Duygu
Cimsit, Canan
Kocakaya, Derya
Mercanci, Zeynep
Balcan, Baran
Ermerak, Onur
Ilgin, Can
Eryuksel, Emel
Karakurt, Sait
Pre-existing Immunocompromised Status as a Preventer of Mortality in COVID-19 Patients: Friend or Foe?
title Pre-existing Immunocompromised Status as a Preventer of Mortality in COVID-19 Patients: Friend or Foe?
title_full Pre-existing Immunocompromised Status as a Preventer of Mortality in COVID-19 Patients: Friend or Foe?
title_fullStr Pre-existing Immunocompromised Status as a Preventer of Mortality in COVID-19 Patients: Friend or Foe?
title_full_unstemmed Pre-existing Immunocompromised Status as a Preventer of Mortality in COVID-19 Patients: Friend or Foe?
title_short Pre-existing Immunocompromised Status as a Preventer of Mortality in COVID-19 Patients: Friend or Foe?
title_sort pre-existing immunocompromised status as a preventer of mortality in covid-19 patients: friend or foe?
topic Infectious Disease
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10186853/
https://www.ncbi.nlm.nih.gov/pubmed/37200662
http://dx.doi.org/10.7759/cureus.37633
work_keys_str_mv AT olgunyıldızelisehnaz preexistingimmunocompromisedstatusasapreventerofmortalityincovid19patientsfriendorfoe
AT vezirduygu preexistingimmunocompromisedstatusasapreventerofmortalityincovid19patientsfriendorfoe
AT cimsitcanan preexistingimmunocompromisedstatusasapreventerofmortalityincovid19patientsfriendorfoe
AT kocakayaderya preexistingimmunocompromisedstatusasapreventerofmortalityincovid19patientsfriendorfoe
AT mercancizeynep preexistingimmunocompromisedstatusasapreventerofmortalityincovid19patientsfriendorfoe
AT balcanbaran preexistingimmunocompromisedstatusasapreventerofmortalityincovid19patientsfriendorfoe
AT ermerakonur preexistingimmunocompromisedstatusasapreventerofmortalityincovid19patientsfriendorfoe
AT ilgincan preexistingimmunocompromisedstatusasapreventerofmortalityincovid19patientsfriendorfoe
AT eryukselemel preexistingimmunocompromisedstatusasapreventerofmortalityincovid19patientsfriendorfoe
AT karakurtsait preexistingimmunocompromisedstatusasapreventerofmortalityincovid19patientsfriendorfoe